Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, under the ticker symbol WWB, marking a significant milestone for the Shanghai-rooted immunology firm.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock sharply higher on its first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening performance by any measure in the current biotech capital markets environment.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
Windward Bio operates in the immunology space, a field that has drawn sustained institutional interest given the broad therapeutic applications ranging from autoimmune disorders to oncology. As a portfolio company of Qiming Venture Partners, one of Asia's prominent venture capital firms, Windward Bio carries backing with an established track record in life sciences investment.
The listing adds to a growing cohort of Asia-linked biotechs seeking access to U.S. public markets via Nasdaq, a preferred venue for clinical-stage companies that may not yet carry commercial revenue. A strong first-day close can ease subsequent capital raises, though biotech valuations remain sensitive to clinical trial readouts and broader risk appetite.
Continue reading at All Financial Services & Investing.